FGP
STOK icon

Freestone Grove Partners’s Stoke Therapeutics STOK Stock Holding History

Freestone Grove Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,776
Closed -$98.3K – 845
2025
Q1 		$98.3K Sell
14,776
-3,273
-18% -$30.5K ﹤0.01% 561
2024
Q4 		$199K Buy
+18,049
New +$222K ﹤0.01% 534

Other funds holding STOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Freestone Grove Partners's STOK Position: Q2 2025 in Review

Freestone Grove Partners sold out of Stoke Therapeutics (STOK) in Q2 2025, closing a stake of 14,776 shares — an estimated $98.3K sold.

Freestone Grove Partners first reported a position in STOK in Q4 2024 and held it in 2 quarters. The position peaked at $199K in Q4 2024. 133 funds tracked by Wall St. Rank hold STOK as of Q2 2025.

  • Freestone Grove Partners reported no remaining Stoke Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 14,776 Stoke Therapeutics shares in Q2 2025, an estimated $98.3K.
  • Freestone Grove Partners first reported a position in Stoke Therapeutics in Q4 2024 and held it in 2 quarters.
  • Freestone Grove Partners's Stoke Therapeutics position peaked at $199K in Q4 2024.
  • 133 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2025.

Based on Freestone Grove Partners's 13F filing for Q2 2025, filed 14 Aug 2025.